

02<sup>nd</sup> November, 2019

The Manager-Listing BSE Limited Phiroze Jeejeebhoy Towers,

Dalal Street, Mumbai-400001

The Manager-Listing National Stock Exchange of India Ltd., Exchange Plaza, Bandra-Kurla Complex Bandra (E)

Mumbai-400051

BSE Code-537291

NSE Code-NATHBIOGEN

Sub - Outcome of Board Meeting. Ref - Regulation 30 and Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements).

We inform you that the Board of Directors of the Company, at its Meeting held today i.e. on 02nd November 2019, has approved the standalone unaudited financial results, for the quarter and half year ended 30th September, 2019.

Pursuant to above-referred regulations, we enclose the following documents.

- 1. Statement of Financial Results, Balance Sheet and Cash Flow Statement, for the quarter and half year ended 30th September 2019.(Annexure-I)
- 2. Limited Review Report of the Statutory Auditors on the aforesaid Financial Results. (Annexure-II)
- 3. Appointment of M.K. Ghatiya and Associates Company Secretaries, as Internal Auditor for head office of the Company and Controlling over other internal auditor of branches. brief profile and disclosure attached as under

Particulars	Details		
Name of Internal Auditor	M. K. Ghatiya and Associates, Company Secretaries.		
Date of appointment Brief Profile	w.e.f. 01st November 2019  Mr. Madhu Kumar Ghatiya Proprietor of M.K. Ghatiya and Associates Company Secretaries. By qualification he's Company Secretary, LLB and M. Com he's also Cleared Chartered Accountant (PE-2).  He has been working in the area of Accounts, Taxation, Finance, Bank Audits apart from Company Secretaries work Since 2002.  He's also internal auditor in some other Companies.		
Disclosure of relationship betw	Director/VMD of the		

Nath House, Nath Road, Aurangabad - 431005 (MS) Tel: 0240-2376314/5/6/7 Email: info@nathseeds.com www.nathbiogenes.com







The Meeting Commenced on 12:00 p.m. and Concluded on 03:45 p.m.


The above information will be made available on the Company's website www.nathbiogenes.com.

You are requested to take the above information on record.

Thanking You

For Nath Bio-Genes (India) Limited

Devinder Khurana Chief Financial Officer





Nath House, Nath Road, Aurangabad - 431005 (MS) Tel: 0240-2376314/5/6/7
 Email: info@nathseeds.com www.nathbiogenes.com

<sup>■ 1,</sup> Chateau Windsor, 86 Veer Nariman Road, Mumbai - 400020 (MS) Tel: 022-22871001, 22875653/4/5



## Wath Bio-Genes (I) Ltd.

STATEMENT OF STANDALONE UNAUDITED RESULTS FOR THE HALF YEAR ENDED ON 30/09/2019

Rs	in	Lac

		Quarter Ended			Six Months Ended		Year Ended	
. No.	Particular's	30/09/2019 Unaudited	30/06/2019 Unaudited	30/09/2018 Unaudited	30/09/2019 Unaudited	30/09/2018 Unaudited	31/03/2019 Audited	
	Income	2102.10	40.000.04	2378.05	18668.36	15074.27	23092.89	
	(a) Revenue from operations (b) Other Operating Income	2136.42	16531.94 62.88	81.68	95.37	146,35	227.36	
	Total Income	2168.91	16594.82	2459.73	18763.73	15220.61	23320.24	
-	a) Cost of Material Consumed	1511.39	4605.58	3663.12	6116.97	5915.83	13061,85	
	b) Purchase of Stock-in-Trade c) Changes in Inventory of Finished Goods &	25,00	133.04	167.57	158.04	190.43	549.18	
	Work in Progress	(1433.83)	3638.15	(3517,95)	2204.31	804.68	(3046.07	
	d) Employee Benefit Expense	339.21	397.36	599.65	* 736.57	1087.55	1642.81	
	e) Finance Costs	148.68	173.06	200.34	321.74	311.84	520.46	
	n Degreciation & Amortisation Expenses	37.50	35.00	35.00	72.50	70.00	144.66 4418.40	
	g) Selling & Distribution Expenses	614.48	3584.80	504.53	4199.29 1027.21	2843.65 984.55	2142.14	
	h) Admin & R&D Expenditure	545.88	481.33	446.87	1027.21	904.00	2142.14	
	7.4.15	1788.31	13048.32	2099.14	14836.63	12208.53	19433.42	
	Total Expenses	380.60	3546.50	360.59	3927.10	3012.08	3886.82	
-	/ Exceptional Items Income/(Expenses)	0.00	0.00	0.00	0.00	0.00	0.00	
	/ Profit Before Tax (III+IV)	380.60	3546.50	360.59	3927.10	3012.08	3886.82	
	Tax Expense				20.40	50.00	10.98	
v	(a) Current Tax	5.71	20.75	0.00	26.46 5.78	0.00	18.7	
	(b) Earlier Year Tax	5.78	0.00	0.00	0.00	0.00	13.79	
	(c) Deferred Tax	0.00	0.00		-			
	II Net Profit for the period (V-VI)	369.11	3525.75	360.59	3894.86	2962.08	a 3843.34	
VI	Other Comprehensive Income							
	1. (a) Items that will not be reclassified to Profit or Loss     (b) Income tax relating to items that will not	0,00	0,00	0.00	0.00	0.00	8.39	
	be reclassified to Profit or Loss	0.00	0.00	0.00	0.00	0.00	0.0	
	(a) Items that will be reclassified to Profit or Loss     (b) Income tax relating to items that will be	0.00	0,00	0,00	0.00	0,00	0.00	
	reclassified to Profit or Loss	0.00	0.00	0.00	0.00	0.00	0.00	
	Total other Comprehensive Income	0.00	0.00	0.00	0.00	0.00	8.3	
	X Total Comprehensive Income for the period (VII +	369.11	3525.75	360,59	3894.86	2962.08	3834.9	
	VIII)  X Paid Up Equity Share Capital (Face Value Rs. 10/- each)	1900.40	1900.40	1900.40	1900,40	1900.40	1900.4	
)	XI Reserves (excluding Revaluation Reserves) as per balance sheet of previous year	52752.52	52383.41	47624.21	52752.52	47984.80	48857.6	
X	(II Earning per share (of Rs 10/- each) (not annualised)  Basic & Diluted	1.94	18,55	1,90	20.49	15.59	20.2	

- (1) The unaudited stand alone financial results, balance sheet and cash flow statement, were reviewed by the Audit Committee in meeting held on 01 November 2019 and were thereafter approved by the Board of Directors at its meeting held on 02 November 2019.
- (2) The company is dealing in one major product segment, i.e. Seed Cultivation.
- (3) This statement is as per Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirement) Regulations, 2015

(4) The figures have been regrouped/rearranged where ever necessary.

ASHOK R. MAJETHIA & CO.

Place: Aurangabad

Date : 02 Nov 2019

**Chartered Accountants** 

ERN No.: 127789W

FOR NATH BIO-GENES (INDIA) LTD

Satish Kagliwal MANAGING DIRECTOR

DIN 00119601

ASHOR MAJETHIA

PROPRIETOR MEMBERSHIP NO.: 124781

	Nath Bio-Genes (In Standalone Statement of A		and the second s
********		The same and analysis	Rs. In La
	Particulares	As at Half Year end	As at Year end
		30.09.2019	31.03.2019
		(Unaudited)	(Audited)
A	ASSETS		(Aunted)
*******	(1) Non Current Assets		
	a) Property, Plant & Equipment	22757.36	22811.5
	b) Capital Work in Progress	0,00	0.0
	c) Other Intangible Assets	340.00	360.0
	d) Intangible Assets under Development	0.00	0.0
	e) Financial Assets		V.C
	(i) Investments	499.74	499.7
	(ii) Others	18.17	18.1
*******	f) Deferred Tax Assets (Net)	72.41	72.4
******	g) Other Non Current Assets	167.94	126.5
	Total Non Current Assets	23855.62	23888.3
	(2) Current Assets	***************************************	4,3000.3
***************************************	la) Inventories	13235.11	15535.6
	b) Financial Assets	A 1.7 A 1.7 / 3 A 1	The same of the sa
www.	(i) Investments	0.00	0.0
**********	(ii) Trade Receivables	12940.77	10802,5
*******	(iii) Cash and Cash Equivalents	2001.55	2137.9
	(iv) Bank balance other than (iii) above	0.00	0.0
	(v) Loans	10834.72	11868.90
*****	c) Current Tax Assets (Net)	237.48	****************************
	d) Other Current Assets	162.37	216.4
-	Total Current Assets	39412.00	156.56
	TOTAL ASSETS	63267.62	40717.95
	EQUITIES AND LIABILITIES	93207.02	64606.33
	1. Shareholders' Fund	***************************************	**************************************
manni	(a) Share capital	1900.40	1000 11
	(b) Reserves and Surplus	52752.53	1900.40
	(c) Money received against share warrants		48857.66
	Sub-total - Shareholders' Fund	0.00	0.00
	2. Share application money pending for allotment	54652.93	50758.06
	3. Minotiries Interest	0.00	Q.00
mil	4. Non-current liabilities	U.AI	0.00
······································	a) Long Term Borrowings	71.80	The latest and the la
marine.	b) Deferred Tax Liabilities	**************************************	50.46
monde	c) Other Long Term Liabilities	0.00	0.00
	i) Long Term Provisions	0.00	0.00
	Sub-total - Non-current liabilities	211.86	188.77
	5. Current Liabilities	283.66	239.23
	) Short Term Borrowings		
	a) Trade Pavables	6587.86	5719.06
-	O) Other Current Liabilities	1084.41	5020.13
	D Short Term Provisions	595.23	2780.33
	Current Tax Liabilities	37.07	37.07
+	AUTEUR TAX LIADHITIES	26.46	52.45
Cr	AND A F TO A PROPER A STEEL A VALUE OF THE PROPERTY AS THE PRO	8331.03	13609.04
1	OTAL - EQUITY AND LIABILITIES	63267.62	64606.33

FOR NATH BIO-GENES (INDIA) LTD

Satish Kagliwal

Place : Aurangabad MANAGING DIRECTOR

Date : 02 Nov 2019 DIN 00119601

ASHOK R. MAJETHIA & CO.
Chartered Accountants
ERN No.: 127 69W

ASHER MAJETHIA MEMBERSHIP NO.: 124781

### Nath Bio-Genes (India) Limited Cash Flow Statement for the half year Ended 30.09.2019 Half Year ended Year ended Particulars 31.03.2019 30.09.2019 (Audited) (Unaudited) A) CASH FLOW FROM OPERATING ACTIVITIES 3,886.82 3.894.87 Nett Profit before Tax & Extra Ordinary items Adjustment for 144.65 Depreciation 12.91 5.35 Provision for Gratucity 10.18 -3.32 Provision for Compensated Absences 321.71 520.46 Interest Paid / Financial Charges -29.33 0.00 Provisoin (Reversal of Provision) for Bad Debts -0.78 -12.88 Profit on sale of Fixed Assets -8.39 0.00 Expenses under Other Comprehensive Income 172.85 73.25 Interest Income 4,342.61 4,226.04 Operating Profit before working capital changes Adjustment for : -2.568.24 -2,138.27 (Increase) / Decrease in Trade Receivables 2,300.51 -3,189.90 (Increase) / Decrease in Inventories -2,045.85 1,034.18 (Increase) / Decrease in Loans & Advances 83.10 -26.85 (Increase) / Decrease in Other Current Assets -3,935.72 1.360.20 Increase / (Decrease) in Trade Payable -2,234.18 -3.28 Increase / (Decrease) in other current liabilities 2.021.36 774.29 Cash Generated from operation before Tax & Extra Income tax Paid -2,293.57 -774.29 Net Cash Flow from Operating Activities - (A) B) CASH FLOW FROM INVESTING ACTIVITIES 8.40 46.90 Sale of fixed assets -32.36 -2,229.55 Purchase of Fixed Assets 73.25 172.85 Interest Received 0.00 -0.02 Purchase of Non Current Investment 41.39 0.00 (Increase) / Decrease in Non Current Assets 2,048.32 Net Cash Flow from Investing Activities - (B) C) CASH FLOW FROM FINANCING ACTIVITIES -520.46 -321.71 Interest Paid / Financial Charges 19.44 21.34 Increase / (Decrease) in Long Term Borrowings 0.00 23.09 Increase / (Decrease) in Long Term Provisions 2,343.79 Increase / (Decrease) in Short Term Borrowings 868.80 0.00 ncrease / (Decrease) in Short Term Unsecured Loan 2,013.99 Nett Cash Flow From Financing Activities - (C) 591.52 -136.37 -2,327,90 Nett increase/Decrease in cash & cash equivalent (A-4,465.83 2,137.93 Opening Cash and Cash Equivalent 2,137,93 2,001.56 CLOSING CASH & CASH EQUIVALENT

FOR NATH BIO-GENES (INDIA) LTD

(my

DIN 00119601

Place: Aurangabad Date : 02 Nov 2019 MANAGING DIRECTOR

ASHOK R. MAJETHIA & CO.

Chartered Accountants FRN No.: 127760W ASHOK R. MAJETHIA PROPRIETOR

**MEMBERSHIP NO.: 124781** 

# ASHOK R. MAJETHIA-

BCom. F.C.A CHARTERED ACCOUNTANT Ashok R. Majethia & Co.
Chartered Accountants
Utsav Complex,
Office No. 7, Bazar Peth,
Dist. Raigad, Khopoli – 410 203
Tel:- (02192) 269908
Mobile:- 9404711539 / 9372169952
Email:- ashokmajethia@redifmail.com

LIMITED REVIEW REPORT

To, The Board of Directors Nath Bio-Genes (India) Limited Aurangabad

- 1. We have reviewed the accompanying statement of unaudited financial results, Standalone Statement of Assets and Liabilities and Cash Flow Statement of Nath Bio-Genes (India) Limited for the quarter ended 30th September 2019 and year to date results for the period 1st April 2019 to 30th September 2019 ("The Statement") being submitted by the Company pursuant to the requirements of regulation 33 of the Securities and Exchange Board of India (Listing Obligation and Disclosure Requirements) Regulation 2015 as modified.
- 2. This statement which is the responsibility of the Company's Management and has been approved by the Board of Directors, has been prepared in accordance with Ind-AS 34- 'Interim Financial Reporting' prescribed under section 133 of the Companies Act., 2013 read with relevant rules issued thereunder and other recognised accounting practices and policies generally accepted in India. Our responsibility is to issue a report on these financial statements based on our review.
- 3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less



assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards except as mentioned in para 5 below in the Basis for qualified opinion and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

### 5. Basis for qualified opinion:

- (a) In respect of inter-corporate Loans / Advances, prima-facie, the company has not complied with the provisions of section 186 of the Act, in as much as these are interest free loans granted to certain parties.
- (b) Investment of Rs. 4,99,40,000 has not been valued at fair market as required under the Ind-AS 113.

M.NO.: 124781 FRN NO.:127769W

For Ashok R Majethia

Chartered Accountants

Ashok Majethia

Proprietor M No: 124781

UDIN: 19124781AAAAB\$ 4317

Place: Aurangabad

Date: 02nd November, 2019